CARIS LIFE SCIENCES, INC. vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Caris and Veracyte both sell advanced diagnostics; only one has finished the income statement. Veracyte's 16.3% operating margin flows through to an identical 16.3% net, the clean conversion of a business past its investment phase, priced at 56 times earnings; Caris earns 2.4% operating, just across the profitability line, at 52.9 times. The near-identical multiples are the finding: the market charges the same for finished and unfinished conversions, betting Caris' tumor-profiling menu scales the way Veracyte's thyroid-and-lung franchise did. Both hold fortress liquidity, current ratios of 7.05 and 9.31, and neither carries real debt. Veracyte's page shows the destination; Caris' shows the journey, at the same fare.
Comparison updated 2026-07-10.
| Metric | CAI | VCYT |
|---|---|---|
| Price | $18.52 | $60.46 |
| Market cap | $5.2B | $4.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 52.9 | 56.0 |
| P/B | 8.82 | 3.66 |
| P/S | 5.77 | 9.07 |
| EV/EBITDA | 37.2 | 56.1 |
| Revenue growth | +91.2% | +16.9% |
| Gross margin | — | 72.7% |
| Operating margin | 2.4% | 16.3% |
| Net margin | 3.8% | 16.3% |
| Return on equity | 5.7% | 6.5% |
| Return on assets | 2.9% | 6.1% |
| Return on invested capital | 8.8% | 5.5% |
| FCF yield | 2.4% | 3.2% |
| Debt / equity | 0.64 | 0.00 |
| Current ratio | 7.05 | 9.31 |
| Altman Z (solvency) | 4.14 | 6.48 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.